{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:18:03Z","timestamp":1762161483156,"version":"3.41.2"},"reference-count":34,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prognostic significance of family with sequence similarity 83, member D (FAM83D) in hepatocellular carcinoma (HCC) patients has not been well-investigated using Gene Expression Omnibus (GEO) series and TCGA database, we compared FAM83D expression levels between tumor and adjacent tissues, and correlated FAM83D in tumors with outcomes and clinico-pathological features in HCC patients. Validated in GSE33006, GSE45436, GSE84402 and TCGA, FAM83D was significantly overexpressed in tumor tissues than that in adjacent tissues (all P&amp;lt;0.01). FAM83D up-regulation was significantly associated with worse overall survival (OS) and disease-free survival (DFS) in HCC patients (Log rank P=0.00583 and P=4.178E-04, respectively). Cox analysis revealed that FAM83D high expression was significantly associated with OS in HCC patients [hazard ratio (HR) = 1.44, 95% confidence interval (CI) = 1.005\u20132.063, P=0.047]. Additionally, patients deceased or recurred\/progressed had significantly higher FAM83D mRNA levels than those living or disease-free (P=0.0011 and P=0.0238, respectively). FAM83D high expression group had significantly more male patients and advanced American Joint Committee on Cancer (AJCC) stage cases (P=0.048 and P=0.047, respectively). FAM83D mRNA were significantly overexpressed in male (P=0.0193). Compared with patients with AJCC stage I, those with AJCC stage II and stage III\u2013IV had significantly higher FAM83D mRNA levels (P = 0.0346 and P=0.0045, respectively). In conclusion, overexpressed in tumors, FAM83D is associated with gender, AJCC stage, tumor recurrence and survival in HCC.<\/jats:p>","DOI":"10.1042\/bsr20181640","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T17:45:35Z","timestamp":1553535935000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma"],"prefix":"10.1042","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-8475","authenticated-orcid":false,"given":"Xuling","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongying","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"2021111619375439800_B1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"2021111619375439800_B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"2021111619375439800_B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2021111619375439800_B4","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/cncr.21461","article-title":"A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy","volume":"104","author":"Shimada","year":"2005","journal-title":"Cancer"},{"key":"2021111619375439800_B5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/hep.24569","article-title":"Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge","volume":"54","author":"Poon","year":"2011","journal-title":"Hepatology"},{"key":"2021111619375439800_B6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ejso.2006.11.015","article-title":"Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients","volume":"33","author":"Tralhao","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"key":"2021111619375439800_B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000367763","article-title":"Personalized clinical trials in hepatocellular carcinoma based on biomarker selection","volume":"5","author":"Zhang","year":"2016","journal-title":"Liver Cancer"},{"key":"2021111619375439800_B8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/CMAR.S156837","article-title":"Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"2021111619375439800_B9","doi-asserted-by":"publisher","first-page":"52597","DOI":"10.18632\/oncotarget.9544","article-title":"FAM83 proteins: fostering new interactions to drive oncogenic signaling and therapeutic resistance","volume":"7","author":"Bartel","year":"2016","journal-title":"Oncotarget"},{"key":"2021111619375439800_B10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1541-7786.MCR-13-0289","article-title":"Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer","volume":"12","author":"Cipriano","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"2021111619375439800_B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1878-0261.12016","article-title":"FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach","volume":"11","author":"Snijders","year":"2017","journal-title":"Mol. Oncol."},{"key":"2021111619375439800_B12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cub.2008.04.041","article-title":"The spindle protein CHICA mediates localization of the chromokinesin Kid to the mitotic spindle","volume":"18","author":"Santamaria","year":"2008","journal-title":"Curr. Biol."},{"key":"2021111619375439800_B13","doi-asserted-by":"publisher","first-page":"e9983","DOI":"10.1371\/journal.pone.0009983","article-title":"Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis","volume":"5","author":"Ramakrishna","year":"2010","journal-title":"PLoS ONE"},{"key":"2021111619375439800_B14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.humpath.2006.11.019","article-title":"A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity","volume":"38","author":"Inamura","year":"2007","journal-title":"Hum. Pathol."},{"key":"2021111619375439800_B15","doi-asserted-by":"publisher","first-page":"24132","DOI":"10.18632\/oncotarget.4432","article-title":"Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma","volume":"6","author":"Liao","year":"2015","journal-title":"Oncotarget"},{"key":"2021111619375439800_B16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2015.01.108","article-title":"FAM83D activates the MEK\/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma","volume":"458","author":"Wang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619375439800_B17","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1093\/nar\/gks789","article-title":"Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells","volume":"40","author":"Huang","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2021111619375439800_B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-017-0680-1","article-title":"STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Cancer"},{"key":"2021111619375439800_B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"2021111619375439800_B20","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"2021111619375439800_B21","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1172\/JCI60517","article-title":"FAM83B mediates EGFR- and RAS-driven oncogenic transformation","volume":"122","author":"Cipriano","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2021111619375439800_B22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.18632\/oncotarget.1027","article-title":"FAM83B-mediated activation of PI3K\/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies","volume":"4","author":"Cipriano","year":"2013","journal-title":"Oncotarget"},{"key":"2021111619375439800_B23","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI60498","article-title":"FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice","volume":"122","author":"Lee","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2021111619375439800_B24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.biopha.2017.11.138","article-title":"miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D","volume":"96","author":"Yan","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"2021111619375439800_B25","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3892\/ol.2012.925","article-title":"Meta-analysis of the expression of the mitosis-related gene Fam83D","volume":"4","author":"Varisli","year":"2012","journal-title":"Oncol. Lett."},{"key":"2021111619375439800_B26","doi-asserted-by":"publisher","first-page":"pii: eaao2341","DOI":"10.1126\/scisignal.aao2341","article-title":"The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms","volume":"11","author":"Fulcher","year":"2018","journal-title":"Sci. Signal."},{"key":"2021111619375439800_B27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1042\/BST20160277","article-title":"The FAM83 family of proteins: from pseudo-PLDs to anchors for CK1 isoforms","volume":"46","author":"Bozatzi","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"2021111619375439800_B28","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.18632\/oncotarget.1581","article-title":"FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7","volume":"4","author":"Wang","year":"2013","journal-title":"Oncotarget"},{"key":"2021111619375439800_B29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.biopha.2017.03.073","article-title":"FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7\/Notch-1 signalling pathway","volume":"90","author":"Mu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"2021111619375439800_B30","doi-asserted-by":"publisher","first-page":"21733","DOI":"10.18632\/oncotarget.15562","article-title":"Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors","volume":"8","author":"Perez-Pena","year":"2017","journal-title":"Oncotarget"},{"key":"2021111619375439800_B31","doi-asserted-by":"crossref","first-page":"74479","DOI":"10.18632\/oncotarget.20157","article-title":"FAM83D, a microtubule-associated protein, promotes tumor growth and progression of human gastric cancer","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"2021111619375439800_B32","first-page":"2587","article-title":"Upregulation of FAM83D promotes malignant phenotypes of lung adenocarcinoma by regulating cell cycle","volume":"6","author":"Shi","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"2021111619375439800_B33","doi-asserted-by":"publisher","first-page":"77495","DOI":"10.18632\/oncotarget.12715","article-title":"FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"2021111619375439800_B34","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.18632\/oncotarget.6620","article-title":"Prognostic significance of FAM83D gene expression across human cancer types","volume":"7","author":"Walian","year":"2016","journal-title":"Oncotarget"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181640\/848180\/bsr-2018-1640.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181640\/848180\/bsr-2018-1640.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:26:11Z","timestamp":1637094371000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/5\/BSR20181640\/219185\/FAM83D-is-associated-with-gender-AJCC-stage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181640","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"type":"print","value":"0144-8463"},{"type":"electronic","value":"1573-4935"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5]]},"article-number":"BSR20181640"}}